Raymond James raises Johnson & Johnson price target to $265

0 min read | Published on 17 Jul 2026, 01:00 AM |Updated on 17 Jul 2026, 01:00 AM

Reviewed by

Radhika SScanX News Team

Key Highlights

Raymond James analyst Jayson Bedford maintained an Outperform rating on Johnson & Johnson and raised the price target to $265 from $258, signaling confidence in the stock's potential.

*this image is generated using AI for illustrative purposes only.

Raymond James analyst Jayson Bedford has maintained an Outperform rating on Johnson & Johnson (NYSE:JNJ) while increasing the price target to $265 from $258. The adjustment reflects a revised valuation outlook for the healthcare conglomerate.

The rating affirmation and target increase highlight the firm's continued confidence in the company's performance trajectory. Investors holding Johnson & Johnson shares may see this revision as an indicator of potential upside.

Analyst Rating and Price Target Details

The following table outlines the revised analyst metrics for Johnson & Johnson:

Metric	Value
Rating	Outperform
Previous Price Target	$258
New Price Target	$265

The new price target of $265 represents an increase over the prior $258 target set by the firm.

What specific factors drove Raymond James to revise their valuation outlook for Johnson & Johnson?

How might Johnson & Johnson's recent performance in its pharmaceutical and medtech segments impact future earnings?

What are the potential risks or challenges that could affect Johnson & Johnson's ability to meet the new price target?

J&J lifts 2026 outlook as Q2 sales rise 6.6% to $25.31B

2 min read | Published on 14 Jul 2026, 07:53 PM |Updated on 16 Jul 2026, 11:49 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Johnson & Johnson raised its full-year 2026 guidance after reporting a 6.6% increase in second-quarter sales to $25.31 billion, driven by robust operational performance. The company now targets annual revenue exceeding $100 billion, with adjusted EPS projected to reach $11.68 at the midpoint. RBC Capital Markets maintained an Outperform rating, citing strong Innovative Medicine momentum and ex-Stelara growth of more than 14%.

*this image is generated using AI for illustrative purposes only.

Johnson & Johnson raised its full-year 2026 guidance after reporting a 6.6% increase in second-quarter sales to $25.31 billion, driven by robust operational performance across its Innovative Medicine and MedTech segments. The company now targets annual revenue exceeding $100 billion for the first time in its 140-year history, with adjusted EPS projected to reach $11.68 at the midpoint. RBC Capital Markets maintained an Outperform rating and a price target of $287, noting that Innovative Medicine momentum is building into 2027 with ex-Stelara growth of more than 14% year-on-year.

Q2 2026 Financial Highlights

Worldwide reported sales increased to $25.31 billion from $23.74 billion in the prior-year period. Operational sales growth, excluding translational currency impact, was 5.6%. Adjusted net earnings rose 5.7% to $7.08 billion, while adjusted diluted EPS increased 4.7% to $2.90. Free cash flow for the year-to-date period was estimated at approximately $8.7 billion.

Metric	Q2 2026	Q2 2025	% Change
Reported Sales	$25,310M	$23,743M	+6.6%
Net Earnings (GAAP)	$5,534M	$5,537M	-0.1%
EPS Diluted (GAAP)	$2.27	$2.29	-0.9%
Adjusted Net Earnings	$7,081M	$6,699M	+5.7%
Adjusted EPS Diluted	$2.90	$2.77	+4.7%
Free Cash Flow (YTD est.)	~$8,700M	$6,214M	—

Segment Performance

The Innovative Medicine segment posted sales of $16.38 billion, up 7.8% reported and 6.8% operational. Growth was led by DARZALEX, CARVYKTI, and TREMFYA, partially offset by headwinds from STELARA and REMICADE. The MedTech segment reported sales of $8.93 billion, up 4.5% reported and 3.6% operational, driven by wound closure, electrophysiology, and contact lenses.

Segment	Q2 2026 Sales	Q2 2025 Sales	Reported Change	Operational Change
Innovative Medicine	$16,384M	$15,202M	+7.8%	+6.8%
MedTech	$8,926M	$8,541M	+4.5%	+3.6%
Worldwide Total	$25,310M	$23,743M	+6.6%	+5.6%

Raised Full-Year 2026 Guidance

Johnson & Johnson increased its full-year 2026 guidance for reported sales to a range of $100.8 billion to $101.4 billion, with a midpoint of $101.1 billion. Adjusted EPS guidance was raised to $11.60 to $11.75, with a midpoint of $11.68, compared to the previous range of $11.45 to $11.65.

Metric	July 2026 Guidance	April 2026 Guidance
Reported Sales (midpoint)	$100.8B–$101.4B / $101.1B	$100.3B–$101.3B / $100.8B
Operational Sales (midpoint)	$100.3B–$100.9B / $100.6B	$99.7B–$100.7B / $100.2B
Adjusted EPS Diluted (midpoint)	$11.60–$11.75 / $11.68	$11.45–$11.65 / $11.55